Tuberculosis Peritonitis During Treatment of Polycythemia Vera with Ruxolitinib

Figures & data

Figure 1 (A, B) ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG-PET/CT) detected the presence of an FDG-avid tumor (arrow) in the ascending colon (A) and peritoneal nodules (arrowheads) (B). (C) A biopsied peritoneal nodule showed epithelioid cell granuloma with partial necrosis on hematoxylin-eosin staining. (D) Abdominal CT showed a thickened peritoneum with massive ascites at the onset of tuberculosis peritonitis.

Table 1 List of Reported MPN Patients Complicated by Mycobacterium Tuberculosis (MTB) Infection During Treatment with Ruxolitinib

Pt. No.	Age/Gender	Type of MPN	Ruxolitinib Treatment			Infection Site			IGRA	Outcome of MTB	Ref.
			Duration Before the Onset of MTB (Week)	Interruption at the Diagnosis of MTB	Re-challenge After Treatment for MTB	Lung	Lymph Node	Others
1	78/F	PMF	88	-	-	+	-	Bone	+	Improved	[^Citation9]
2	82/M	PMF	8	+	-	+	-	-	NA	Improved	[^Citation10]
3	78/F	PMF	NA	+	-	+	+	-	NA	Improved	[^Citation11]
4	NA/M	PMF	NA	NA	-	-	+	-	NA	NA	[^Citation12]
5	65/F	PV→SMF	16	+	+	-	+	-	-	Improved	[^Citation13]
6	62/F	PMF	36	+	+	+	+	-	NA	Improved	[^Citation14]
7	69/M	PMF	3	+	+	+	+	-	+	Improved	[^Citation15]
8	73/M	PMF	24	+	NA	+	-	-	+	Deceased	[^Citation16]
9	73/M	PV→SMF	16	+	NA	+	-	Brain	+	Deceased	[^Citation17]
10	78/M	PV	28	+	-	-	-	Peritoneum	－	Improved	Present case

Abbreviations: Pt, patient; No, number; M, male; F, female; MPN, myeloproliferative neoplasms; PMF, primary myelofibrosis; PV, polycythemia vera; SMF, secondary myelofibrosis; MTB, mycobacterium tuberculosis; IGRA, interferon-gamma release assay; NA, not available.

Branco B, Metsu D, Dutertre M, et al. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. Ann Hematol. 2016;95(7):1207–1209. doi:10.1007/s00277-016-2684-027113251

 PubMed Web of Science ®Google Scholar

Chen YH, Lee CH, Pei SN. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma. 2015;56(5):1528–1529. doi:10.3109/10428194.2014.96308225213182

 PubMed Web of Science ®Google Scholar

Shamil E, Cunningham D, Wong BL, Jani P. Ruxolitinib associated tuberculosis presenting as a neck lump. Case Rep Infect Dis. 2015;2015:284168.26788384

 PubMedGoogle Scholar

Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report. BMC Res Notes. 2012;5(1):552. doi:10.1186/1756-0500-5-55223039051

 PubMedGoogle Scholar

Palandri F, Polverelli N, Catani L, Vianelli N. Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge. Ann Hematol. 2015;94(3):519–520. doi:10.1007/s00277-014-2183-025172457

 PubMed Web of Science ®Google Scholar

Hopman RK, Lawrence SJ, Oh ST. Disseminated tuberculosis associated with ruxolitinib. Leukemia. 2014;28(8):1750–1751. doi:10.1038/leu.2014.10424625550

 PubMed Web of Science ®Google Scholar

Abidi MZ, Haque J, Varma P, et al. Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib. Case Rep Hematol. 2016;2016:2389038.27843657

 PubMedGoogle Scholar

Tsukamoto Y, Kiyasu J, Tsuda M, et al. Fatal disseminated tuberculosis during treatment with ruxolitinib plus prednisolone in a patient with primary myelofibrosis: a case report and review of the literature. Intern Med. 2018;57(9):1297–1300. doi:10.2169/internalmedicine.9165-1729279479

 PubMed Web of Science ®Google Scholar

Lescuyer S, Ledoux MP, Gravier S, et al. Tuberculosis and atypical mycobacterial infections in ruxolitinib-treated patients with primary or secondary myelofibrosis or polycythemia vera. Int J Infect Dis. 2019;80:134–136. doi:10.1016/j.ijid.2019.01.00230639623

 PubMed Web of Science ®Google Scholar